Evidence of low quality suggests that lactoferrin supplementation to enteral feeds with or without probiotics decreases late-onset sepsis and NEC stage II or III in preterm infants without adverse effects .
BACKGROUND Lactoferrin , a normal component of human colostrum and milk , can enhance host defenses and may be effective for prevention of sepsis and necrotizing enterocolitis ( NEC ) in preterm neonates .
To assess the safety and effectiveness of lactoferrin supplementation to enteral feeds for prevention of sepsis and NEC in preterm neonates Secondary objectives 1 .
To determine the effects of lactoferrin supplementation to enteral feeds to prevent neonatal sepsis and /or NEC on duration of positive-pressure ventilation , development of chronic lung disease ( CLD ) or periventricular leukomalacia ( PVL ) , length of hospital stay to discharge among survivors , and adverse neurological outcomes at two years of age or later2 .
To determine the adverse effects of lactoferrin supplementation for prophylaxis of neonatal sepsis and /or NECWhen data were available , we analyzed the following subgroups.1 .
Gestational age < 32 weeks and 32 to 36 weeks2 .
Type of feeding : breast milk versus formula milk SEARCH METHODS : We used the search strategy of the Cochrane Neonatal Review Group ( CNRG ) to up date our search in December 2016 .
Randomized Controlled Trial of Lactoferrin for Prevention of Sepsis in Peruvian Neonates Less than 2500 g
Background : Lactoferrin ( LF ) is a broad-spectrum antimicrobial and immunomodulatory milk glycoprotein . Objective : To determine the effect of bovine LF on the prevention of the first episode of late-onset sepsis in Peruvian infants . Methods : We conducted a pilot r and omized placebo-controlled double blind study in infants with a birth weight ( BW ) less than 2500 g in 3 Neonatal Units in Lima . Patients were r and omized to receive bovine LF 200mg/kg/d or placebo for 4 weeks . Results : One hundred and ninety neonates with a BW of 1591 ± 408 g and a gestational age of 32.1 ± 2.6 weeks were enrolled . Overall , 33 clinical ly defined first late-onset sepsis events occurred . The cumulative sepsis incidence in the LF group was 12/95 ( 12.6 % ) versus 21/95 ( 22.1 % ) in the placebo group , and 20 % ( 8/40 ) versus 37.5 % ( 15/40 ) for infants less than or equal to 1500 g. The hazard ratio of LF , after adjustment by BW , was 0.507 ( 95 % CI : 0.249–1.034 ) . There were 4 episodes of culture-proven sepsis in the LF group versus 4 in the placebo group . Considering that children did not received the intervention until the start of oral or tube feeding , we ran a secondary exploratory analysis using time since the start of the treatment ; in this model , LF achieved significance . There were no serious adverse events attributable to the intervention . Conclusions : Overall sepsis occurred less frequently in the LF group than in the control group . Although the primary outcome did not reach statistical significance , the confidence interval is suggestive of an effect that justifies a larger trial
Evidence of low quality suggests that lactoferrin supplementation to enteral feeds with or without probiotics decreases late-onset sepsis and NEC stage II or III in preterm infants without adverse effects .
BACKGROUND Lactoferrin , a normal component of human colostrum and milk , can enhance host defenses and may be effective for prevention of sepsis and necrotizing enterocolitis ( NEC ) in preterm neonates .
To assess the safety and effectiveness of lactoferrin supplementation to enteral feeds for prevention of sepsis and NEC in preterm neonates Secondary objectives 1 .
To determine the effects of lactoferrin supplementation to enteral feeds to prevent neonatal sepsis and /or NEC on duration of positive-pressure ventilation , development of chronic lung disease ( CLD ) or periventricular leukomalacia ( PVL ) , length of hospital stay to discharge among survivors , and adverse neurological outcomes at two years of age or later2 .
To determine the adverse effects of lactoferrin supplementation for prophylaxis of neonatal sepsis and /or NECWhen data were available , we analyzed the following subgroups.1 .
Gestational age < 32 weeks and 32 to 36 weeks2 .
Type of feeding : breast milk versus formula milk SEARCH METHODS : We used the search strategy of the Cochrane Neonatal Review Group ( CNRG ) to up date our search in December 2016 .